The American Journal of Medicine
Volume 122, Issue 6 , Pages 497-506 , June 2009

Helping Women Choose Appropriate Hormonal Contraception: Update on Risks, Benefits, and Indications

  • Abby L. Spencer, MD, MS

      Affiliations

    • Department of Medicine, Section of General Internal Medicine, Allegheny General Hospital, Pittsburgh, Pa
    • Corresponding Author InformationRequests for reprints should be addressed to Abby L. Spencer, MD, MS, Department of Medicine, Division of General Internal Medicine, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212
    • ,
  • Rachel Bonnema, MD, MS

      Affiliations

    • Department of Medicine, Section of General Internal Medicine, University of Nebraska Medical Center, Omaha
    • ,
  • Megan C. McNamara, MD, MSc

      Affiliations

    • Department of Medicine, Section of General Internal Medicine, Case Western Reserve University, Cleveland, Ohio

References 

  1. Finer S, Henshaw K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38(2):90–96
  2. Schwartz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med. 2007;147:370–376
  3. Trussell J. Contraceptive efficacy. In:  Hatcher RA,  Trussell J,  Nelson AL,  Cates W, et al. editor. Contraceptive Technology. 19th revised edition. New York NY: Ardent Media; 2007;p. 747–756
  4. Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004;70:3–10
  5. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1998;57:169–181
  6. ACOG Committee on Practice Bulletins–Gynecology. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–1472
  7. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke. 1998;29:2277–2284
  8. MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke. 2007;38:2438–2445
  9. Petitti D. Combination estrogen–progestin oral contraceptives. N Engl J Med. 2003;349(15):1443–1450
  10. World Health Organization. Low-dose combined oral contraceptives. http://www.who.int/reproductive-health/publications/mec/3_cocs.pdfAccessed August 20, 2008
  11. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025–2032
  12. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11(5):513–525
  13. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501
  14. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314
  15. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. Hum Reprod. 1997;12:1851–1863
  16. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg. Contraception. 2007;75(1):16–22
  17. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception. 2006;73(3):229–234
  18. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006;74(6):439–445
  19. Davis AR, Kroll R, Soltes B, et al. Return to menses after continuous use of a low-dose oral contraceptive. Obstet Gynecol. 2006;107:3S
  20. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821
  21. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112:1979–1984
  22. U.S. Food and Drug Administration. Yasmin. http://www.fda.gov/Cder/consumerinfo/druginfo/yasmin.HTMAccessed August 19, 2008
  23. Schlaff WD, Lynch AM, Hughes HD, et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol. 2004;190:943–951
  24. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266
  25. Coffee A, Kuehl TK, Willis SA, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311–1319
  26. Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77(3):162–170
  27. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;(3):CD004695
  28. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77(2 Suppl 2):S13–S18
  29. Ortho Evra Patch. http://www.fda.gov/cder/drug/infopage/orthoevra/qa2008.htmAccessed October 12, 2008
  30. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med. 1996;335(2):108–114
  31. Novak A, de la Loge C, Abetz L, van der Meulen A. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception. 2003;67:187–194
  32. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera trademark sign): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75–87
  33. Haider S, Darney PD. Injectable contraception. Clin Obstet Gynecol. 2007;50(4):898–906
  34. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev. 2007;(2):CD006261
  35. Mattson RH, Rebar RW. Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol. 1993;168:2027–2032
  36. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception. 1998;57(5):315–324
  37. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer (A pooled analysis of the World Health Organization and New Zealand studies). JAMA. 1995;273(10):799–804
  38. Kaunitz AM. Depo-Provera's black box: time to reconsider?. Contraception. 2005;72:165–167
  39. Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone aceteate: recovery following discontinuation. Contraception. 2006;74:90–99
  40. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–487
  41. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76
  42. World Health Organization. WHO statement on hormonal contraception and bone health. Geneva, Switzerland: WHO; July 2005;http://www.who.int/reproductive-health/family_planning/docs/hormonal_contraception_bone_health.pdfAccessed October 14, 2008
  43. Hohmann H, Crenin MD. The contraceptive implant. Clin Obstet Gynecol. 2007;50:907–917
  44. Beerthuizen R, van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod. 2000;15(1):118–122
  45. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):4–12
  46. Choice of contraceptives. Treat Guidel Med Lett. 2007;5(64):101–108
  47. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Hum Reprod. 1999;14:976–981
  48. Makarainen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998;69:714–721
  49. Funk S, Miller MM, Mishell DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71:319–326
  50. Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care. 2008;13(S1):29–36
  51. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study (World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception). Contraception. 1998;57:315–324
  52. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception. 2004;70:437–441
  53. Vieria CS, Ferriani RA, Garcia AA, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod. 2007;22:2196–2201

 Funding: None.

 Conflict of Interest: None.

 Authorship: Each author was involved in the conception, design, and the writing of the manuscript, and approved the submitted version of the manuscript.

PII: S0002-9343(09)00106-5

doi: 10.1016/j.amjmed.2009.01.016

The American Journal of Medicine
Volume 122, Issue 6 , Pages 497-506 , June 2009

Article Tools